Ranbaxy Announces Recall of Antibiotic in U.S.
On the heels of a recall of one lot of their skin care product, pharmaceutical manufacturer Ranbaxy Pharmaceuticals, Inc. has also announced that they are voluntarily recalling two lots of the antibiotic drug from the U.S. market. Drug maker Ranbaxy recently recalled one lot of their 40 milligram Sotret Isotretinoin capsules, a drug that can help acne sufferers have cleaner skin. The company’s second recall involves Lots No 1910779 and 1910782, both with an expiration date of May 2010.
The antibiotic is designed to be mixed with water to form a lotion that can be applied directly to the skin. The company issued the recall after some users complained that when the product was mixed with water, it changed color in ways that previous batches had not. It is unknown if anyone has been injured or disfigured by Sotret Isotretinoin, but anyone with unused product is encouraged to stop using the skin treatment immediately and contact the manufacturer. The FDA is investigating the company for failing to comply with recommended manufacturing practices at two of its plants.
Most pharmaceutical recalls involve drugs that have caused very serious health complications and even death. California pharmaceutical litigation lawyer Samer Habbas knows very well that companies that manufacture products of any kind have a responsibility to ensure that their products are safe to use. As an experienced Los Angeles pharmaceutical litigation lawyer, he has been helping victims and their families recover damages from the manufacturers of defective and dangerous drugs for many years. If you or someone you care for has been injured or lost due to prescription medication, call 888.848.5084 today to speak with Southern California pharmaceutical litigation attorney Samer Habbas and receive answers to your questions.
Resource link: www.topnews.in/ranbaxy-announces-recall-us-market-2258933